Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
Background Paclitaxel (PTX) resistance is a major obstacle in the treatment of triple-negative breast cancer (TNBC). Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells. In this study, we so...
Main Authors: | Panpan Wang, Dan Song, Danhong Wan, Lingyu Li, Wenhui Mei, Xiaoyun Li, Li Han, Xiaofeng Zhu, Li Yang, Yu Cai, Ronghua Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2020-06-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/9281.pdf |
Similar Items
-
The anti-platelet activity of panaxadiol fraction and panaxatriol fraction of Korean Red Ginseng in vitro and ex vivo
by: Yuan Yee Lee, et al.
Published: (2023-09-01) -
Ginsenoside Rg5 Sensitizes Paclitaxel—Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel—And Enhances the Anticancer Effect of Paclitaxel
by: Janani Ramesh, et al.
Published: (2022-06-01) -
Ginsenoside compound K induces mitochondrial apoptosis in human hepatoma cells through Bclaf1-mediated modulation of ERK signaling
by: Jiaxin Chen, et al.
Published: (2022-12-01) -
Magnolin Inhibits Paclitaxel-Induced Cold Allodynia and ERK1/2 Activation in Mice
by: Nari Kim, et al.
Published: (2023-06-01) -
Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species
by: Xiaonan Li, et al.
Published: (2023-07-01)